Skip to main content

Biocryst Pharma Inc(BCRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low9.24
Day High10.11
Open:9.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Biocryst Pharma Inc

Select a category then submit the form to load news
Tipranks
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)
GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value
Tipranks
BioCryst Earnings Call Highlights Profits, Pipeline Momentum
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Quoin Pharmaceuticals (QNRX), Biodesix (BDSX)
Tipranks
Bank of America Securities Remains a Buy on BioCryst (BCRX)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Enovis (ENOV), BioCryst (BCRX)
Tipranks
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Fate Therapeutics (FATE)
Tipranks
BioCryst Boosts HAE Franchise With Astria Acquisition, Guidance
GlobeNewswire
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
Tipranks
Evercore ISI Resumes Coverage with a Buy Rating on BioCryst (BCRX)
GlobeNewswire
BioCryst to Present at Upcoming Investor Conference
GlobeNewswire
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
GlobeNewswire
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX)
Tipranks
Bank of America Securities Keeps Their Buy Rating on BioCryst (BCRX)
Tipranks
BioCryst Closes Blackstone Loan and Astria Acquisition
GlobeNewswire
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema 
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), BioCryst (BCRX)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Elicio Therapeutics (ELTX)
Tipranks
BioCryst Updates ORLADEYO Revenue Outlook and Guidance
GlobeNewswire
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
Tipranks
TD Cowen Reaffirms Their Buy Rating on BioCryst (BCRX)
Tipranks
Wedbush Sticks to Their Buy Rating for BioCryst (BCRX)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Wave Life Sciences (WVE) and Alkermes (ALKS)
Tipranks
BioCryst’s Avoralstat Study: A New Hope for Diabetic Macular Edema?
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioCryst (BCRX), Arcus Biosciences (RCUS) and Amicus (FOLD)
Tipranks
Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks
Tipranks
BioCryst (BCRX) Gets a Buy from Wedbush

Profile

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.